ELEVATE: Elacestrant Combinations for the Treatment of ER+ HER2- Metastatic Breast Cancer After CDK4/6 Inhibitor
Condition: Breast Cancer
Sponsor: Stemline Therapeutics, Inc.
Full Title
Protocol STML-ELA-0222: A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer
Study Treatment
Arm A: Elacestrant + Alpelisib
Arm B: Elacestrant + Everolimus
Arm C: Elacestrant + Palbociclib
Arm D: Elacestrant + Ribociclib
Eligibility/Info
Eligible patients will have ER+, HER2- metastatic breast cancer that has not been treated with chemotherapy in the metastatic setting but that has progressed after up to 2 prior lines of hormonal therapy that included a CDK4/6 inhibitor. Patients in arm A (alpelisib combination arm) must also have a documented PIK3CA mutation.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
Locations
Babylon Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology
Need More Information?
Our team is here to help answer your questions and guide you through your options.